Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Betaseron Administered in a Needle-Free System for Multiple Sclerosis RICHMOND, Calif.--July 1, 1996 -- Berlex Laboratories announces an agreement with Bioject (NASDAQ:BJCT) under which Bioject will manufacture and sell to Berlex a unique needle-free drug delivery system for use by multiple sclerosis patients to self-administer Betaseron(R) (Interferon beta-1b) for subcutaneous injection. Berlex's goal is to make the Betaseron Needle-Free System(TM) available to patients in 1997. "The Betaseron Needle-Free System(TM) is being developed to help patients administer Betaseron(R) therapy," said Jeffrey Latts, M.D., Vice President, Clinical Research and Development. "Patients have told us that injection with a needle can be challenging and can deter them from beginning or continuing therapy. The Betaseron Needle-Free System(TM) is expected to provide Betaseron(R) users with a much improved method of drug delivery." The Betaseron Needle-Free System(TM) uses a burst of carbon dioxide to propel a stream of medicine through the skin without a needle. Besides alleviating "needle-phobia," the system can enhance consistency of administration. In addition, the Betaseron Needle-Free System(TM) should provide for easier, one-step reconstitution of Betaseron(R) without the use of needles. Betaseron(R) will be the only interferon therapy for MS to provide a convenient means of self-administration without requiring needles. Designed specifically for the self-injection of Betaseron(R), the Betaseron Needle-Free System(TM) is a small, portable, hand-held device. Berlex is in the process of submitting an application to the FDA for the device, and expects review to be completed in less than one year. The Betaseron Needle-Free System(TM) will be offered through MS Centers, disease management programs with health care providers, and directly to patients through Berlex's Multiple Sclerosis Pathways patient education program. "Patients have told us that they want this technology, and we are very pleased to say that we are well on our way to providing it," said Dr. Latts. "The Betaseron Needle-Free System(TM) is a result of Berlex's ongoing efforts to continuously improve Betaseron(R) therapy and the services we offer to people with MS." Needle-free systems have been used to administer drug therapies for a number of years. The Betaseron Needle-Free System(TM) represents a new generation of improved technology in needle-free systems. It offers Betaseron(R) users this technology in a form that is both convenient and reliable and has been specifically designed for use by multiple sclerosis patients on Betaseron(R) therapy. Soon, MS patients will be able to take Betaseron(R) therapy without using needles. Berlex Laboratoriesintroduced the first therapeutic beta interferon treatment for multiple sclerosis (MS), into the U.S. market in July 1993. More than five years of clinical trial data and experience treating more than 50,000 patients attest to the safety and efficacy of Betaseron(R) for the treatment of relapsing-remitting MS. Bioject, located in Portland, Oregon, is the leading manufacturer of needle-free injection systems. Bioject also has been honored with the Seal of Acceptance from the Alliance of Children's Hospitals, Inc. for its needle-free injection systems. E-mail this page to a friend or colleague! To print, use this version